Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer

Probably, patients with de novo (synchronous) and recurrent (metachronous) oligometastatic hormone-sensitive prostate cancer have different oncologic outcomes. Thus, we are challenged with different scenarios in clinical practice, where different treatment options may apply. In the last years, sever...

Descripción completa

Detalles Bibliográficos
Autores principales: Preisser, Felix, Chun, Felix. K.-.H., Banek, Severine, Wenzel, Mike, Graefen, Markus, Steuber, Thomas, Tilki, Derya, Mandel, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Pacific Prostate Society 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498729/
https://www.ncbi.nlm.nih.gov/pubmed/34692582
http://dx.doi.org/10.1016/j.prnil.2020.12.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498729/
https://www.ncbi.nlm.nih.gov/pubmed/34692582
http://dx.doi.org/10.1016/j.prnil.2020.12.003

Ejemplares similares